Loading
The dose needed to shrink a tumour may be higher than the dose needed to keep it from growing back. Trials that lower the dose once a response is achieved could reduce long-term side effects without losing control.
Randomised trials in which patients achieving a defined response (radiographic, molecular or biochemical) after induction are allocated to continue full dose or step down to a maintenance dose (e.g., 50 percent), with resumption of full dose on progression. Precedents include dose reduction of dasatinib and other TKIs in chronic-phase CML after deep response, and maintenance de-escalation strategies in myeloma; the proposal extends the approach to solid-tumour targeted agents and ADCs where chronic toxicity accumulates.
Shares Wrong doses, Imatinib, Toxicity and quality of life are undervalued, Small-molecule kinase inhibitors.
Shares Wrong doses, Imatinib, Toxicity and quality of life are undervalued, Small-molecule kinase inhibitors.
Shares Wrong doses, Toxicity and quality of life are undervalued, Small-molecule kinase inhibitors.
Shares Chemotherapy roadmap: mustard gas → curative combinations → the warhead inside smarter drugs, Wrong doses, Toxicity and quality of life are undervalued.
Shares Wrong doses, Trastuzumab deruxtecan, Antibody-drug conjugate (ADC).
Shares Wrong doses, Imatinib, Small-molecule kinase inhibitors.
Shares Wrong doses, Toxicity and quality of life are undervalued, Small-molecule kinase inhibitors.
Shares Wrong doses, Trastuzumab deruxtecan, Toxicity and quality of life are undervalued, Antibody-drug conjugate (ADC).